Targets › TBXA2R
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 3; Cardiovascular, Immunology, Respiratory; next expected readout Jan 2027.
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. (UniProt, P21731)
Open in Phaseline: the race on TBXA2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| iVascular S.L.U. | 1-month DAPT Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo | P2RY12, TBXA2R | Phase 3 | Coronary Artery Disease | Jan 2027 |
| Cumberland Pharmaceuticals | Ifetroban Sodium Thromboxane A2 receptor (TP receptor) antagonist | TBXA2R | Phase 2 | Scleroderma, Diffuse; Idiopathic Pulmonary Fibrosis | Jan 2028 |
Coronary Artery Disease (1) Scleroderma, Diffuse (1) Idiopathic Pulmonary Fibrosis (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.